Showcases Stock ranks Forex

Pmv Pharmaceuticals Inc (PMVP)
17.12  0.07 (0.41%) 08-08 16:00
Open: 17.1 Pre. Close: 17.05
High: 17.27 Low: 16.455
Volume: 417,485 Market Cap: 780M
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 17.28 - 17.331 17.331 - 17.389
Low: 16.298 - 16.359 16.359 - 16.427
Close: 17.009 - 17.104 17.104 - 17.21
Stock Technical Analysis
Target: Six months: 20.18
One year: 23.57
Support: Support1: 14.81
Support2: 13.29
Resistance: Resistance1: 17.28
Resistance2: 20.18
Pivot: 15.26
Moving Averages: MA(5): 16.03
MA(20): 15.31
MA(100): 15.27
MA(250): 19.83
MACD: MACD(12,26): 0.54
Signal(12,26,9): 0.39
%K %D: %K(14,3): 94.35
%D(3): 79.11
RSI: RSI(14): 62.51
52-Week: High: 35.75
Low: 8.99
Change(%): -49.4
Average Vol(K): 3-Month: 1794
10-Days: 531
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ PMVP ] has closed below upper band by 1.1%. Bollinger Bands are 31% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Tue, 02 Aug 2022
Comparing PMV Pharmaceuticals (NASDAQ:PMVP) & NovaBay Pharmaceuticals (NYSE:NBY) - Defense World

Mon, 25 Jul 2022
DekaBank Deutsche Girozentrale Has $379000 Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World

Mon, 18 Jul 2022
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors - GlobeNewswire

Thu, 09 Jun 2022
Is PMV Pharmaceuticals Inc (PMVP) a Smart Choice in Biotechnology Thursday? - InvestorsObserver

Wed, 08 Jun 2022
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference - GlobeNewswire

Tue, 07 Jun 2022
PMVP stock slips after early data for lead candidate in solid tumors (NASDAQ:PMVP) - Seeking Alpha

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 45.38
Shares Float (M) 22.56
% Held by Insiders 7.43
% Held by Institutions 133.33
Shares Short (K) 14340
Shares Short Prior Month (K) 12110
Stock Financials
EPS -1.110
Book Value (p.s.) 7.160
Profit Margin
Operating Margin
Return on Assets (ttm) -12.2
Return on Equity (ttm) -20.2
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -1.431
Qtrly Earnings Growth
Operating Cash Flow (M) -51.66
Levered Free Cash Flow (M) -30.88
Stock Valuation
PE Ratio -15.42
PEG Ratio -0.37
Price to Book value 2.39
Price to Sales
Price to Cash Flow -15.04
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android